Business
Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
– Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":" – Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a development candidate - a next-generation PRMT5 inhibitor for MTAP-deleted solid tumors – – Declared TNG260 as a development candidate - an inhibitor of an undisclosed synthetic lethal target that reverses the immune evasion effect of STK11 loss-of-function mutations – – Strong cash position of $450 million expected to support advancing discovery and clinical pipeline into second half of 2024 – CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2022 and provided business highlights. “We’ve had a strong start to 2022, including IND clearance and Fast Track Designation from the FDA for TNG908, our lead PRMT5 inhibitor program. We are making good progress advancing TNG908 into the clinic and expect to dose our first patient in the Phase 1/2 clinical trial for the treatment of MTAP-deleted solid tumors in the second quarter of this year,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “Additionally, our development candidates, TNG462, a next-generation PRMT5 inhibitor for MTAP-deleted solid tumors and TNG260, an inhibitor of an undisclosed synthetic lethal target that reverses the immune evasion effect of STK11 loss-of-function mutations, are in IND-enabling studies. Finally, with a strong current cash position, we are confident in our ability to advance our programs into the second half of 2024.” Recent Business Highlights TNG908 IND cleared and granted Fast Track Designation (FTD); first-in-human clinical trial is now open for enrollment. As disclosed in February 2022, the U.S. Food and Drug Administration (FDA) granted FTD to TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to selectively kill cancer cells with methylthioadenosine phosphorylase (MTAP) deletions. FTD is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fulfill an unmet medical need, with the potential to allow drugs to reach more patient...